Keyphrases
PARP Inhibitor (PARPi)
100%
Homologous Recombination Repair
100%
Homologous Recombination Deficiency
100%
BRCA mutation
60%
Regulatory Agencies
40%
Tumor
40%
Genomic Instability
40%
Tumor Cells
20%
Cancer Treatment
20%
Prostate Cancer
20%
Breast Cancer
20%
Clinical Activity
20%
BRCA2
20%
Diagnostic Test
20%
Clinical Significance
20%
Pancreatic Cancer
20%
Ovarian Cancer
20%
Tumor Subtype
20%
Breast Cancer Susceptibility Gene 1 (BRCA1)
20%
Patient Selection
20%
Biological Basis
20%
Diagnostic Methods
20%
Clinical Validation
20%
Multiple Tumors
20%
Companion Diagnostics
20%
Platinum Sensitivity
20%
Inhibitor Sensitivity
20%
Complementary Diagnostic Test
20%
Mutation Mutation
20%
Homologous Recombination Repair Pathway
20%
Medicine and Dentistry
Homologous Recombination
100%
Recombination Repair
100%
PARP Inhibitor
100%
BRCA Mutation
37%
Neoplasm
25%
Genomic Instability
25%
Patient Selection
12%
Tumor Cell
12%
BRCA1
12%
BRCA2
12%
Proteus Syndrome
12%
Cancer Treatment
12%
Pancreatic Cancer
12%
Pharmacology, Toxicology and Pharmaceutical Science
Nicotinamide Adenine Dinucleotide Adenosine Diphosphate Ribosyltransferase Inhibitor
100%
Neoplasm
60%
Malignant Neoplasm
20%
Multiple Cancer
20%